Fmr LLC Erasca, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Fmr LLC holds 230,487 shares of ERAS stock, worth $684,546. This represents 0.0% of its overall portfolio holdings.

Number of Shares

230,487

Previous 138,651 66.24%

Holding current value

$684,546

Previous $285,000 90.53%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.79 - $2.63 $164,386 - $241,528	91,836 Added 66.24%	230,487 $543,000
Q1 2024 May 13, 2024	BUY	$1.67 - $2.55 $134,800 - $205,833	80,719 Added 139.33%	138,651 $285,000
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.49 $83,394 - $124,343	49,937 Added 624.6%	57,932 $123,000
Q3 2023 Nov 13, 2023	BUY	$1.97 - $2.91 $11,420 - $16,869	5,797 Added 263.74%	7,995 $15,000
Q2 2023 Aug 11, 2023	BUY	$2.57 - $3.3 $4,407 - $5,659	1,715 Added 355.07%	2,198 $6,000
Q1 2023 May 11, 2023	SELL	$2.74 - $4.44 $25.9 Million - $41.9 Million	-9,436,761 Reduced 99.99%	483 $1,000
Q4 2022 Feb 13, 2023	SELL	$3.89 - $8.57 $34.6 Million - $76.1 Million	-8,884,803 Reduced 48.49%	9,437,244 $40.7 Million
Q3 2022 Nov 10, 2022	BUY	$5.82 - $10.68 $252,541 - $463,426	43,392 Added 0.24%	18,322,047 $143 Million
Q2 2022 Aug 12, 2022	BUY	$4.58 - $8.72 $2.14 Million - $4.08 Million	468,142 Added 2.63%	18,278,655 $102 Million
Q1 2022 May 13, 2022	BUY	$8.6 - $15.48 $41.2 Million - $74.1 Million	4,788,563 Added 36.77%	17,810,513 $153 Million
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $63.5 Million - $116 Million	5,079,927 Added 63.96%	13,021,950 $203 Million
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $138 Million - $193 Million	7,942,023 New	7,942,023 $169 Million

Others Institutions Holding ERAS

# of Institutions

133

Shares Held

205M

Call Options Held

3.1K

Put Options Held

142K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $363M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account